
Sign up to save your podcasts
Or


Harry Destecroix was studying for his PhD at Bristol University when he co-founded Ziylo. Based on 20 years of Bristol chemistry research, the spin-out company created a new technology that can be developed to treat diabetes more effectively. It's a breakthrough that led to its acquisition by pharmaceutical firm, Novo Nordisk, in a deal reportedly worth up to 600 million pounds. Harry has also founded the incubator, Science Creates and is the founding managing partner of SCVC, a venture capital firm. Harry tells Evan Davis why his own experience of spinning out a company has made him passionate to help other early-stage companies in the Bristol area – whether that’s providing lab space, finance or advice.
(Image: Harry Destecroix Credit: Peter Schiazza, Copyright: Science Creates)
By BBC Radio 44.7
3232 ratings
Harry Destecroix was studying for his PhD at Bristol University when he co-founded Ziylo. Based on 20 years of Bristol chemistry research, the spin-out company created a new technology that can be developed to treat diabetes more effectively. It's a breakthrough that led to its acquisition by pharmaceutical firm, Novo Nordisk, in a deal reportedly worth up to 600 million pounds. Harry has also founded the incubator, Science Creates and is the founding managing partner of SCVC, a venture capital firm. Harry tells Evan Davis why his own experience of spinning out a company has made him passionate to help other early-stage companies in the Bristol area – whether that’s providing lab space, finance or advice.
(Image: Harry Destecroix Credit: Peter Schiazza, Copyright: Science Creates)

7,613 Listeners

378 Listeners

885 Listeners

1,051 Listeners

54 Listeners

35 Listeners

5,472 Listeners

1,798 Listeners

1,762 Listeners

1,037 Listeners

2,103 Listeners

2,093 Listeners

781 Listeners

72 Listeners

237 Listeners

78 Listeners

116 Listeners

630 Listeners

136 Listeners

3,149 Listeners

1,639 Listeners

3,037 Listeners

817 Listeners

186 Listeners

51 Listeners